AMBONI, Marianna
 Distribuzione geografica
Continente #
NA - Nord America 4.972
EU - Europa 2.134
AS - Asia 2.075
SA - Sud America 377
OC - Oceania 53
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 5
Totale 9.637
Nazione #
US - Stati Uniti d'America 4.907
SG - Singapore 738
CN - Cina 520
RU - Federazione Russa 392
IT - Italia 391
BR - Brasile 345
UA - Ucraina 339
DE - Germania 293
HK - Hong Kong 248
IE - Irlanda 217
TR - Turchia 176
SE - Svezia 148
VN - Vietnam 143
KR - Corea 132
EE - Estonia 107
GB - Regno Unito 83
FI - Finlandia 73
CA - Canada 44
IN - India 36
AU - Australia 30
FR - Francia 30
NZ - Nuova Zelanda 23
JP - Giappone 20
BD - Bangladesh 16
CZ - Repubblica Ceca 14
AR - Argentina 12
NL - Olanda 12
AT - Austria 9
MX - Messico 9
PL - Polonia 8
VE - Venezuela 7
ZA - Sudafrica 7
IL - Israele 6
IQ - Iraq 6
PK - Pakistan 6
AE - Emirati Arabi Uniti 5
BE - Belgio 5
EU - Europa 5
KE - Kenya 5
UZ - Uzbekistan 5
JM - Giamaica 4
NP - Nepal 4
CL - Cile 3
CO - Colombia 3
BH - Bahrain 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
ES - Italia 2
ET - Etiopia 2
ID - Indonesia 2
IR - Iran 2
MA - Marocco 2
OM - Oman 2
PE - Perù 2
PY - Paraguay 2
SA - Arabia Saudita 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BO - Bolivia 1
BS - Bahamas 1
BW - Botswana 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DZ - Algeria 1
GA - Gabon 1
GT - Guatemala 1
HR - Croazia 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
ME - Montenegro 1
MN - Mongolia 1
NI - Nicaragua 1
PA - Panama 1
RO - Romania 1
SV - El Salvador 1
TJ - Tagikistan 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 9.637
Città #
Ann Arbor 1.105
Princeton 518
Chandler 509
Wilmington 468
Jacksonville 429
Singapore 299
Houston 248
Hong Kong 243
Ashburn 205
Dublin 204
Woodbridge 201
Izmir 165
Dong Ket 136
Beijing 120
Nanjing 112
Moscow 109
Tallinn 107
Andover 104
Boardman 86
Salerno 69
Munich 65
Pellezzano 64
Düsseldorf 55
Norwalk 53
Dearborn 44
Shenyang 43
Nanchang 39
Fairfield 34
Mestre 34
Naples 34
Hebei 29
Redwood City 26
Jiaxing 25
São Paulo 23
Los Angeles 21
Changsha 19
San Francisco 19
Dallas 18
Rome 18
Tianjin 18
Pune 17
Milan 16
Nuremberg 16
San Diego 16
The Dalles 15
Washington 15
Casoria 14
Rio de Janeiro 14
Turku 13
Auckland 11
Belo Horizonte 11
Guangzhou 11
New York 11
Sydney 11
Columbus 10
West Jordan 10
Chennai 8
Montreal 8
Amsterdam 7
Cambridge 7
Jinan 7
Santa Maria A Vico 7
Wuhan 7
Ankara 6
Brasília 6
Carapicuíba 6
Council Bluffs 6
Dhaka 6
Dormagen 6
Fuzhou 6
Hefei 6
Napoli 6
Ribeirão Preto 6
Seattle 6
Stockholm 6
Anápolis 5
Atlanta 5
Boston 5
Brussels 5
Curitiba 5
Fukushima 5
Guarulhos 5
Hangzhou 5
Kunming 5
London 5
Melbourne 5
Nairobi 5
Sant'arpino 5
Tokyo 5
Adelaide 4
Brno 4
Brooklyn 4
Fisciano 4
Frankfurt am Main 4
Lappeenranta 4
Las Vegas 4
Osaka 4
Osasco 4
Ottawa 4
Padova 4
Totale 6.566
Nome #
Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients 158
Anxiety in early Parkinson's disease: Validation of the Italian observer-rated version of the Parkinson Anxiety Scale (OR-PAS) 142
A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. 137
Step length predicts executive dysfunction in Parkinson’s disease: a 3-year prospective study 135
Apathy in untreated, de novo patients with Parkinson’s disease: validation study of Apathy Evaluation Scale 133
Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study 129
Increased bilirubin levels in de novo Parkinson's disease 115
Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. 111
Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease 110
A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. 105
Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment 103
Resting-state functional connectivity associated with mild cognitive impairment in Parkinson’s disease 102
Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson's disease. 101
An easy tool to improve accuracy in pre-diagnostic Parkinson's disease population 100
A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease 99
Gender and non motor fluctuations in Parkinson's disease: A prospective study 98
Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study 97
Serum uric acid is associated with apathy in early, drug-naïve Parkinson’s disease 97
The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. 94
Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study 94
Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease 94
Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson’s disease 93
Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study 93
Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease 91
A longitudinal study of cognitive dysfunction in patients affected by Parkinson’s disease with and without freezing of gait 91
Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease 88
Quitting smoking: An early non-motor feature of Parkinson's disease? 87
Short-latency afferent inhibition in patients with Parkinson’s disease and freezing of gait 87
Bisphenol A glucuronidation in patients with Parkinson's disease 87
Assessment of apathy minimising the effect of motor dysfunctions in Parkinson’s disease: a validation study of the dimensional apathy scale 87
Abnormal eating behaviors in progressive supranuclear palsy. 86
The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. 86
Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. 85
Regional Gray Matter Atrophy in Patients with Parkinson Disease and Freezing of Gait. 84
Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson's disease: a prospective longitudinal study. 83
Segmental progression of cardinal motor symptoms in Parkinson's disease: A pilot study suggesting a practical approach to rate disease course in the early stages. 82
Gait patterns in Parkinsonian patients with or without mild cognitive impairment. 81
Caffeine consumption and the 4-year progression of de novo Parkinson's disease 81
Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease. 80
Presence and progression of non-motor symptoms in relation to uric acid inde novoParkinson's disease 80
Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease 80
The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: A 4-year longitudinal study 79
Music Therapy for Motor and Nonmotor Symptoms of Parkinson's Disease: A Prospective, Randomized, Controlled, Single-Blinded Study 78
Parkinson’s disease and the spectrum of Lewy body disease 78
Comment on Szewczyk-Krolikowski et al.: The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort 77
Uric acid relates to dopamine transporter availability in Parkinson's disease. 76
Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system 76
Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. 76
Effect of Global Postural Rehabilitation program on spatiotemporal gait parameters of parkinsonian patients: a three-dimensional motion analysis study. 76
Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness aspresenting symptoms of PARK-2 75
Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? 75
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients 72
Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease 72
Resting-state brain connectivity in patients with Parkinson's disease and freezing of gait. 71
Resting brain networks in patients with Parkinson's disease and freezing of gait 70
Gender differences in non-motor symptoms in early Parkinson's disease: A 2-years follow-up study on previously untreated patients. 70
Do Subjective Memory Complaints Herald the Onset of Mild Cognitive Impairment in Parkinson Disease? 69
Cognitive contributions to gait and falls: Evidence and implications 68
Mutation in theSYNJ1Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism 68
Vestibular impairment and adaptive postural imbalance in parkinsonian patients with lateral trunk flexion 68
Caratteristiche Cliniche 68
Classifying Different Stages of Parkinson’s Disease Through Random Forests 68
Ropinirole as a treatment of restless legs syndrome in patients on chronichemodialysis: an open randomized crossover trial versus levodopa sustainedrelease 67
Neuropsychological correlates of theory of mind in patients withearly Parkinson's disease. 67
Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease 66
Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkindisease 66
Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. 65
Apathy in Parkinson's disease: differences between caregiver's report and self-evaluation 65
Comparing PIGD and Akinetic-Rigid subtyping of Parkinson Disease and their stability over time 65
The "eye of the tiger" sign in pure akinesia with gait freezing. 64
Metabolomics in Parkinson's disease 64
Freezing of gait and executive functions in patients with Parkinson's disease. 63
Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson’s disease 63
A metabolomic signature of treated and drug-naïve patients with Parkinson’s disease: a pilot study 62
null 61
Mild cognitive impairment in drug-naive patients with PD is associated withcerebral hypometabolism 61
Future thinking in Parkinson's disease: An executive function? 61
Hemi-restless legs syndrome induced by clebopride 61
Comparative neuropsychological profile of pathological gambling, hypersexuality and compulsive eating in Parkinson’s disease. 61
“Response to Apomorphine in early Parkinson’s disease”. 61
Parkinsonism and essential tremor in a family with pseudo-dominant inheritance ofPARK2: an FP-CIT SPECT study 60
Exercise dependence induced by pramipexole in Parkinson's Disease-a case report. 59
Ropinirole as treatment of restless leg sindrome in patients on chrnic hemodyalisis: an open randomized, crossover trial versus levodopa sustained release 59
Freezing of gait and executive functions in patients with Parkinson’s disease 59
Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients 58
Resting-state brain networks in patients with Parkinson's disease and impulse control disorders 58
Serum IGF-1 is associated with cognitive functions in early, drug-naive Parkinson's disease 58
Longitudinal Changes Of Dopamine Transporter In Early-Onset Parkin Disease Measured With 123Fr-Cit Spect 58
Gait Analysis in Progressive Supranuclear Palsy Phenotypes. 58
Neuropsychiatric disturbances in parkinsonian patients with and without freezing of gait 57
Neuropsychological Correlates Of Major Depressive Episode In Parkinson’s Diesease 57
Gait patterns and cognition in Parkinson's disease 57
Impact of anxiety, apathy and reduced functional autonomy on perceived quality of life in Parkinson's disease 54
Olfaction in Homozygous and Heterozygous SYNJ1 Arg258Gln Mutation Carriers 54
Development of software tool for quantitative gait assessment in Parkinsonian patients with and without Mild Cognitive Impairment 54
Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: our experience on one hundred and thirty-eight healthy subjects 54
The use of smell identification test in Parkinson's disease in Italy: Preliminary data 54
Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy. 52
Demenza nella malattia di Parkinson 52
A quantitative analysis of muscular co-activation on EMG signals in spastic patients treated with Botulinum toxin 52
Totale 7.863
Categoria #
all - tutte 42.289
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.289


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021722 3 55 62 0 107 60 83 6 68 3 95 180
2021/2022829 9 2 12 14 6 1 7 33 112 117 120 396
2022/20231.274 154 67 37 114 203 295 11 111 185 12 61 24
2023/2024772 44 105 40 42 29 90 25 63 35 57 108 134
2024/20252.220 78 20 31 180 80 182 273 203 320 263 296 294
2025/2026371 371 0 0 0 0 0 0 0 0 0 0 0
Totale 10.032